Literature DB >> 33430516

Comparison of Short- and Long-Term Prognosis between ST-Elevation and Non-ST-Elevation Myocardial Infarction.

Frédéric Bouisset1,2, Jean-Bernard Ruidavets2, Jean Dallongeville3, Marie Moitry4,5, Michele Montaye3, Katia Biasch4, Jean Ferrières1,2.   

Abstract

BACKGROUND: Available data comparing long-term prognosis according to the type of acute coronary syndrome (ACS) are scarce, contradictory, and outdated. Our aim was to compare short- and long-term mortality in ST-elevated (STEMI) and non-ST-elevated myocardial infarction (non-STEMI) ACS patients.
METHODS: Patients presenting with an inaugural ACS during the year 2006 and living in one of the three areas in France covered by the Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) registry were included.
RESULTS: A total of 1822 patients with a first ACS-1121 (61.5%) STEMI and 701 (38.5%) non-STEMI-were included in the study. At the 28-day follow-up, the mortality rates were 6.7% and 4.7% (p = 0.09) for STEMI and non-STEMI patients, respectively, and after adjustment of potential confounding factors, the 28-day probability of death was significantly lower for non-STEMI ACS patients (Odds Ratio = 0.58 (0.36-0.94), p = 0.03). At the 10-year follow-up, the death rates were 19.6% and 22.8% (p = 0.11) for STEMI and non-STEMI patients, respectively, and after adjustment of potential confounding factors, the 10-year probability of death did not significantly differ between non-STEMI and STEMI events (OR = 1.07 (0.83-1.38), p = 0.59). Over the first year, the mortality rate was 7.2%; it then decreased and stabilized at 1.7% per year between the 2nd and 10th year following ACS.
CONCLUSION: STEMI patients have a worse vital prognosis than non-STEMI patients within 28 days following ACS. However, at the 10-year follow-up, STEMI and non-STEMI patients have a similar vital prognosis. From the 2nd year onwards following the occurrence of a first ACS, the patients become stable coronary artery disease patients with an annual mortality rate in the 2% range, regardless of the type of ACS they initially present with.

Entities:  

Keywords:  acute coronary syndrome; coronary heart disease; prognosis

Year:  2021        PMID: 33430516     DOI: 10.3390/jcm10020180

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  5 in total

1.  ST-segment elevation versus non-ST-segment elevation myocardial infarction in current smokers after newer-generation drug-eluting stent implantation.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seung-Jun Lee; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

2.  A Novel Biomarker Scoring System Alone or in Combination with the GRACE Score for the Prognostic Assessment in Non-ST-Elevation Myocardial Infarction.

Authors:  Yao Yao; Chunlai Shao; Xiaoye Li; Zi Wang; Chengchun Zuo; Yan Yan; Qianzhou Lv
Journal:  Clin Epidemiol       Date:  2022-08-02       Impact factor: 5.814

3.  The Effects of Percutaneous Coronary Intervention on the Flow in Acute Coronary Syndrome Patients-Geometry in Focus.

Authors:  Agnes Orsolya Racz; Ildiko Racz; Gabor Tamas Szabo; Aron Uveges; Zsolt Koszegi; Bence Penczu; Rudolf Kolozsvari
Journal:  J Pers Med       Date:  2022-07-31

4.  Development and validation of a predictive model for adverse left ventricular remodeling in NSTEMI patients after primary percutaneous coronary intervention.

Authors:  Lili Wang; Tao Liu; Chaofan Wang; Haochen Xuan; Xianzhi Xu; Jie Yin; Xiaoqun Li; Junhong Chen; Dongye Li; Tongda Xu
Journal:  BMC Cardiovasc Disord       Date:  2022-08-27       Impact factor: 2.174

5.  Biodata Mining of Differentially Expressed Genes between Acute Myocardial Infarction and Unstable Angina Based on Integrated Bioinformatics.

Authors:  Siyu Guo; Zhihong Huang; Xinkui Liu; Jingyuan Zhang; Peizhi Ye; Chao Wu; Shan Lu; Shanshan Jia; Xiaomeng Zhang; Xiuping Chen; Miaomiao Wang; Jiarui Wu
Journal:  Biomed Res Int       Date:  2021-09-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.